MiNK Therapeutics (INKT) announced the appointment of Colonel Ret. John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases
- Mink Therapeutics’ Earnings Call: Clinical Progress Amid Financial Challenges
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- MiNK Therapeutics: Promising Clinical Trials and Growth Prospects Lead to Buy Rating
- MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright